Skip to Content
Merck
All Photos(1)

Documents

SML0147

Sigma-Aldrich

Drospirenone

≥98% (HPLC)

Synonym(s):

6β,7β:15β,16β -Dimethylene-3-oxo-17α-pregn-4-ene-21,17-carbolactone, Dihydrospirorenone

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C24H30O3
CAS Number:
67392-87-4
Molecular Weight:
366.49
EC Number:
266-679-2
MDL number:
MFCD00867350
UNSPSC Code:
51111800
PubChem Substance ID:
329825195
NACRES:
NA.77

Assay

≥98% (HPLC)

form

powder

optical activity

[α]/D -180 to -195°, c = 1 in methanol

storage condition

desiccated

color

white to tan

solubility

DMSO: ≥15

originator

Bayer

storage temp.

2-8°C

SMILES string

C[C@]12CCC(=O)C=C1[C@@H]3C[C@@H]3[C@@H]4[C@@H]2CC[C@@]5(C)[C@H]4[C@@H]6C[C@@H]6[C@@]57CCC(=O)O7

InChI

1S/C24H30O3/c1-22-6-3-12(25)9-17(22)13-10-14(13)20-16(22)4-7-23(2)21(20)15-11-18(15)24(23)8-5-19(26)27-24/h9,13-16,18,20-21H,3-8,10-11H2,1-2H3/t13-,14+,15-,16+,18+,20-,21+,22-,23+,24+/m1/s1

InChI key

METQSPRSQINEEU-HXCATZOESA-N

Gene Information

human ... NR3C2(4306) , PGR(5241)

Looking for similar products? Visit Product Comparison Guide

Application

Drospirenone has been used as a progestogen agent in pond snail and fish.
Drospirenone was tested for genotoxicity in rat and human hepatocytes.

Biochem/physiol Actions

Drospirenone is a fourth-generation progestin that has antimineralocorticoid, and antiandrogenic activity in addition to potent progestogenic activity. In two recent studies drospirenone appeared to double the risk of venous thromboembolism compared to levonorgestrel, although other studies found little added risk.

Features and Benefits

This compound is featured on the Nuclear Receptors (Steroids) page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
This compound was developed by Bayer. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Pictograms

Health hazard
GHS08

Signal Word

Danger

Hazard Statements

H360

Precautionary Statements

P201 - P308 + P313

Hazard Classifications

Repr. 1B

Storage Class Code

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Customers Also Viewed

Slide 1 of 1

1 of 1

Mifepristone ≥98%

Sigma-Aldrich

M8046

Mifepristone

Complex molecular changes induced by chronic progestogens exposure in roach, Rutilus rutilus
Maasz G, et al.
Ecotoxicology and Environmental Safety, 139, 9-17 (2017)
Kadriye Aydin et al.
Contraception, 87(3), 358-362 (2012-08-18)
Limited data are available regarding the potential effects of oral contraceptives (OCs) on body fat distribution particularly in lean women with polycystic ovary syndrome (PCOS). In the current study, we aimed to evaluate the influence of ethinyl estradiol and drospirenone
Laureen M Lopez et al.
The Cochrane database of systematic reviews, (2)(2), CD006586-CD006586 (2009-04-17)
Premenstrual syndrome (PMS) is a common problem. Premenstrual dysphoric disorder (PMDD) is a severe form of PMS. Combined oral contraceptives (COCs), which have both progestin and estrogen, have been examined for their ability to relieve premenstrual symptoms. A COC containing
Antonietta Martelli et al.
Mutation research, 536(1-2), 69-78 (2003-04-16)
Sex steroids, due to the generally negative responses observed in routinely employed standard genotoxicity assays, are considered epigenetic carcinogens. Some doubts on this conviction are raised by the results of recent studies providing evidence that cyproterone acetate and two structural
Apurva Motivala et al.
Drugs, 67(5), 647-655 (2007-03-28)
The use of combined estrogen/progesterone has been shown to result in an increased cardiovascular risk in randomised double-blinded trials. However, these studies used oral progestogen (progestin) preparations, which lack anti-mineralocorticoid activity and have suboptimal anti-androgenic activity compared with progesterone. Drospirenone
View All Related Papers

Articles

Nuclear Receptors (Steroids)

We offers many products related to Nuclear Receptors (Steroids) for your research needs.

Nuclear Receptors (Steroids)

We offers many products related to Nuclear Receptors (Steroids) for your research needs.

Nuclear Receptors (Steroids)

We offers many products related to Nuclear Receptors (Steroids) for your research needs.

Nuclear Receptors (Steroids)

We offers many products related to Nuclear Receptors (Steroids) for your research needs.

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service